Jay Birnbaum

Dr. Jay Birnbaum is a dermatology consultant specializing in ethical and OTC drugs, medical devices, and cosmeceuticals. His experience spans the areas of discovery, formulations, clinical, regulatory and marketing. He has been involved in the development and commercialization of numerous drug and consumer products and brands, including Lamisil antifungal products, Cyclosporine Neoral and Elidel for inflammatory skin diseases, Apligraf living skin equivalent, Kybella for submental fat and LaPrairie Skin Caviar. Dr. Birnbaum is a co-founder & former Chief Medical Officer of Kythera Biopharmaceuticals (acquired by Allergan in 2015), and co-founder & Chief Scientific Officer of Hallux Pharmaceuticals. Dr. Birnbaum was VP Clinical Research and then VP Global Project Management, at Novartis/Sandoz, where he was also responsible for strategic planning and development of the company's dermatology portfolio. Previously, he held management positions at both the Medical and Consumer Product Divisions of American Cyanamid Company (Wyeth). He has served as a member of the board of directors of Sonoma Pharmaceuticals (Nasdaq:SNOA), Hallux Inc., and Excaliard Pharmaceuticals (acquired by Pfizer in 2011), and many Science Advisory Boards. He received his Ph.D. in pharmacology from the University of Wisconsin.